Venture Map · Round
Oncostellae — Other · €500K
Announced 2024-03-19 · Santiago de Compostela · Biotech
CDTI Innovación, through its Innvierte programme, agreed to enter the capital of Galician biopharma Oncostellae alongside the venture fund Bio & Tech Smart Capital FCRE (managed by Noso Capital). CDTI committed €500K; the total round size and Bio & Tech's ticket were not disclosed, and no venture stage was named. Oncostellae is developing OST-122 (JAK inhibitor for inflammatory bowel disease), OST-499 and OST-664.
RoundOther
Amount€500K
LeadNot disclosed
Date2024-03-19
CitySantiago de Compostela
SectorBiotech
The company
Investors 2
BBio & Tech Smart Capital FCRE (Noso Capital)
CCDTI Innovación (Innvierte)
www.cdti.es